• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    3/25/25 4:15:56 PM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email
    ilmn-20250325
    0001110803FALSEMarch 25, 202500011108032025-03-252025-03-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Form 8-K
    Current Report

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): March 24, 2025
    ilmnlogoa19.jpg
    Illumina, Inc.
    (Exact name of registrant as specified in its charter)

    001-35406
    (Commission File Number)
    Delaware 33-0804655
    (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)

    5200 Illumina Way, San Diego, CA 92122
    (Address of principal executive offices) (Zip code)

    (858) 202-4500
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.01 par valueILMNThe NASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐    
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o    



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    (b) On March 25, 2025, Stephen P. MacMillan, notified the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) of his intention to resign as a director of the Company, effective as of March 28, 2025. Mr. MacMillan’s resignation is not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.
    (d) On March 25, 2025, the Board elected Keith A. Meister to serve on the Board beginning March 28, 2025. Mr. Meister will stand for election at the Company’s 2025 annual meeting of stockholders to serve for a one-year term commencing with such meeting. There is no arrangement or understanding between Mr. Meister and any other person pursuant to which he was selected as a director. In addition, Mr. Meister is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Mr. Meister will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 4, 2024.
    Item 7.01 Regulation FD Disclosure.
    On March 25, 2025, the Company issued a press release to announce the changes in Board membership described in Items 5.02(b) and (d) above. In addition, Dr. Scott Gottlieb has been elected non-executive Chair of Illumina’s Board, effective as of March 28, 2025. Such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.



    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.
    99.1    Press release dated March 25, 2025 issued by Illumina, Inc.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)    




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
        
     
    ILLUMINA, INC.
     
    Date:March 25, 2025By:
    /s/ SCOTT DAVIES
     Name:Scott Davies
     Title:Chief Legal Officer




    Exhibit Index
    Exhibit NumberDescription
    99.1
    Press release dated March 25, 2025 issued by Illumina, Inc.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    SEC Filings

    View All

    SEC Form 144 filed by Illumina Inc.

    144 - ILLUMINA, INC. (0001110803) (Subject)

    2/18/26 4:22:07 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    2/5/26 4:09:49 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    1/30/26 9:06:44 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

    40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B). Staggered starts and new flow cells go live across the customer base in the coming weeks.Tog

    2/23/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina To Webcast Upcoming Investor Conference

    SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor ConferenceTD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026The fireside chat is scheduled for 12:10pm PT (3:10pm ET).The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com. A replay will be archived on Illumina's website for at least 30 days following the event.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequenci

    2/17/26 3:10:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation

    DENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible. Recent developments among genomics and AI-enabled biotechnology companies suggest that AI-driven pattern recognition is emerging as a foundational layer for CRISPR-based innovation, with implications spanning human health and advanced biologically assembled materials. Illumina (NASDAQ:ILMN), the global leader in DNA sequencing, recently secured U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expanding access to broad genomic profiling in routine cancer care. Increased rei

    2/10/26 9:29:10 AM ET
    $GH
    $ILMN
    $RXRX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 1,259 shares, decreasing direct ownership by 4% to 33,435 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/18/26 4:57:18 PM ET
    $ILMN
    Medical Specialities
    Health Care

    VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 694 shares, decreasing direct ownership by 5% to 13,229 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/18/26 4:55:17 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 1,164 shares, decreasing direct ownership by 5% to 22,721 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/18/26 4:54:17 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Citigroup reiterated coverage on Illumina with a new price target

    Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

    3/4/25 8:10:42 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

    Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:

    2/5/26 4:06:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

    SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info

    1/12/26 4:07:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

    Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basisGAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per shareFor fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no ch

    10/30/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care